Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Первичная и вторичная профилактика рака шейки матки (по материалам рекомендаций Американского общества клинической онкологии, март 2017 г.) Часть II
Первичная и вторичная профилактика рака шейки матки (по материалам рекомендаций Американского общества клинической онкологии, март 2017 г.) Часть II
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
29. Bailey HH, Chuang LT, du Pont NC et al. American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention. J Clin Oncol 2016; 34 (15): 1803–12. DOI: 10.1200/JCO.2016.67.2014. Epub 2016 Apr 11.
30. Dorell C, Yankey D, Kennedy A, Stokley S. Factors that influence parental vaccination decisions for adolescents, 13 to 17 years old: National Immunization Survey-Teen, 2010. Clin Pediatr (Phila) 2013; 52 (2): 162–70. DOI: 10.1177/0009922812468208. Epub 2012 Dec 6.
31. Gerend MA, Madkins K, Phillips G, Mustanski B. Predictors of Human Papillomavirus Vaccination Among Young Men Who Have Sex With Men. Sex Transm Dis 2016; 43 (3): 185–91. DOI: 10.1097/OLQ.0000000000000408.
32. Gerend MA, Shepherd MA, Lustria ML, Shepherd JE. Predictors of provider recommendation for HPV vaccine among young adult men and women: findings from a cross-sectional survey. Sex Transm Infect 2016; 92 (2): 104–7. DOI: 10.1136/sextrans-2015-052088. Epub 2015 Aug 21.
33. Rosenthal SL, Weiss TW, Zimet GD et al. Predictors of HPV vaccine uptake among women aged 19–26: importance of a physician's recommendation. Vaccine 2011; 29 (5): 890–5. DOI: 10.1016/j.vaccine.2009.12.063. Epub 2010 Jan 5.
34. Lee Mortensen G, Adam M, Idtaleb L. Parental attitudes towards male human papillomavirus vaccination: a pan-European cross-sectional survey. BMC Public Health 2015; 15: 624. DOI: 10.1186/s12889-015-1863-6.
35. Campos NG, Tsu V, Jeronimo J et al. When and how often to screen for cervical cancer in three low- and middle-income countries: A cost-effectiveness analysis. Papillomavirus Res 2015; 1: 38–58.
36. National Cancer Institute: Cervical Cancer Screening–Health Professional Version (PDQR). Bethesda, MD, National Cancer Institute, 2016.
37. Darragh TM, Colgan TJ, Thomas Cox J et al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol 2013; 32 (1): 76–115. DOI: 10.1097/PGP.0b013e31826916c7.
38. Moyer VA. U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 156 (12): 880–91, W312. DOI: 10.7326/0003-4819-156-12-201206190-00424.
39. Ikenberg H, Bergeron C, Schmidt D et al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst 2013; 105 (20): 1550–7. DOI: 10.1093/jnci/djt235. Epub 2013 Oct 4.
40. Qiao YL, Jeronimo J, Zhao FH et al. Lower cost strategies for triage of human papillomavirus DNA-positive women. Int J Cancer 2014; 134 (12): 2891–901. DOI: 10.1002/ijc.28616. Epub 2013 Dec 3.
41. Mirabello L, Sun C, Ghosh A et al. Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population. J Natl Cancer Inst 2012; 104 (7): 556–65. DOI: 10.1093/jnci/djs135. Epub 2012 Mar 23.
42. Wentzensen N, Sun C, Ghosh A et al. Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst 2012; 104 (22): 1738–49. DOI: 10.1093/jnci/djs425. Epub 2012 Oct 23.
43. Wentzensen N, Nason M, Schiffman M et al. No evidence for synergy between human papillomavirus genotypes for the risk of high-grade squamous intraepithelial lesions in a large population-based study. J Infect Dis 2014; 209 (6): 855–64. DOI: 10.1093/infdis/jit577. Epub 2013 Oct 31.
44. Joste NE, Ronnett BM, Hunt WC et al. Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer. Cancer Epidemiol Biomarkers Prev 2015; 24 (1): 230–40. DOI: 10.1158/1055-9965.EPI-14-0775. Epub 2014 Nov 2.
45. Kinde I, Bettegowda C, Wang Y et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 2013; 5 (167): 167ra4. DOI: 10.1126/scitranslmed.3004952.
30. Dorell C, Yankey D, Kennedy A, Stokley S. Factors that influence parental vaccination decisions for adolescents, 13 to 17 years old: National Immunization Survey-Teen, 2010. Clin Pediatr (Phila) 2013; 52 (2): 162–70. DOI: 10.1177/0009922812468208. Epub 2012 Dec 6.
31. Gerend MA, Madkins K, Phillips G, Mustanski B. Predictors of Human Papillomavirus Vaccination Among Young Men Who Have Sex With Men. Sex Transm Dis 2016; 43 (3): 185–91. DOI: 10.1097/OLQ.0000000000000408.
32. Gerend MA, Shepherd MA, Lustria ML, Shepherd JE. Predictors of provider recommendation for HPV vaccine among young adult men and women: findings from a cross-sectional survey. Sex Transm Infect 2016; 92 (2): 104–7. DOI: 10.1136/sextrans-2015-052088. Epub 2015 Aug 21.
33. Rosenthal SL, Weiss TW, Zimet GD et al. Predictors of HPV vaccine uptake among women aged 19–26: importance of a physician's recommendation. Vaccine 2011; 29 (5): 890–5. DOI: 10.1016/j.vaccine.2009.12.063. Epub 2010 Jan 5.
34. Lee Mortensen G, Adam M, Idtaleb L. Parental attitudes towards male human papillomavirus vaccination: a pan-European cross-sectional survey. BMC Public Health 2015; 15: 624. DOI: 10.1186/s12889-015-1863-6.
35. Campos NG, Tsu V, Jeronimo J et al. When and how often to screen for cervical cancer in three low- and middle-income countries: A cost-effectiveness analysis. Papillomavirus Res 2015; 1: 38–58.
36. National Cancer Institute: Cervical Cancer Screening–Health Professional Version (PDQR). Bethesda, MD, National Cancer Institute, 2016.
37. Darragh TM, Colgan TJ, Thomas Cox J et al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol 2013; 32 (1): 76–115. DOI: 10.1097/PGP.0b013e31826916c7.
38. Moyer VA. U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 156 (12): 880–91, W312. DOI: 10.7326/0003-4819-156-12-201206190-00424.
39. Ikenberg H, Bergeron C, Schmidt D et al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst 2013; 105 (20): 1550–7. DOI: 10.1093/jnci/djt235. Epub 2013 Oct 4.
40. Qiao YL, Jeronimo J, Zhao FH et al. Lower cost strategies for triage of human papillomavirus DNA-positive women. Int J Cancer 2014; 134 (12): 2891–901. DOI: 10.1002/ijc.28616. Epub 2013 Dec 3.
41. Mirabello L, Sun C, Ghosh A et al. Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population. J Natl Cancer Inst 2012; 104 (7): 556–65. DOI: 10.1093/jnci/djs135. Epub 2012 Mar 23.
42. Wentzensen N, Sun C, Ghosh A et al. Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst 2012; 104 (22): 1738–49. DOI: 10.1093/jnci/djs425. Epub 2012 Oct 23.
43. Wentzensen N, Nason M, Schiffman M et al. No evidence for synergy between human papillomavirus genotypes for the risk of high-grade squamous intraepithelial lesions in a large population-based study. J Infect Dis 2014; 209 (6): 855–64. DOI: 10.1093/infdis/jit577. Epub 2013 Oct 31.
44. Joste NE, Ronnett BM, Hunt WC et al. Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer. Cancer Epidemiol Biomarkers Prev 2015; 24 (1): 230–40. DOI: 10.1158/1055-9965.EPI-14-0775. Epub 2014 Nov 2.
45. Kinde I, Bettegowda C, Wang Y et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 2013; 5 (167): 167ra4. DOI: 10.1126/scitranslmed.3004952.
Авторы
Дубровина Светлана Олеговна –
д-р мед. наук, проф., проф. каф. акушерства
и гинекологии №1 ФГБОУ ВО РостГМУ
Минздрава России, гл. науч. сотр.
ФГБУ РНИИАП.
д-р мед. наук, проф., проф. каф. акушерства
и гинекологии №1 ФГБОУ ВО РостГМУ
Минздрава России, гл. науч. сотр.
ФГБУ РНИИАП.
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.